In this video, Monica Avila, MD, MPH, discusses final OS results from the phase 3 ROSELLA trial assessing the addition of relacorilant to nab-paclitaxel for patients with platinum-resistant ovarian cancer.
In the trial, presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, patients were randomly assigned to relacorilant (Lifyorli, Corcept Therapeutics) plus nab-paclitaxel (Abraxane, Bristol Myers Squibb) or nab-paclitaxel alone.
According to Avila, a gynecologic oncologist at Moffitt Cancer Center, the median OS with the relacorilant regimen was 16 months vs. 12 months with nab-paclitaxel monotherapy. At 18 months, 46% of patients in the combination arm remained alive vs. 27% in the monotherapy arm.
For more information:
Monica Avila, MD, MPH, can be reached at monica.avila@moffitt.org.
Sources/Disclosures
Source:
Healio Interviews
Reference:
- Olawaiye AB, et al. Final overall survival results from the phase 3 ROSELLA trial: Relacorilant plus nab-paclitaxel vs. nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer. Presented at: Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; April 10-13, 2026; San Juan, Puerto Rico.
Disclosures:
Avila reports no relevant financial disclosures.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply